As of Apr 29
| -0.19 / -3.45%|
The 4 analysts offering 12-month price forecasts for Progenics Pharmaceuticals Inc have a median target of 10.00, with a high estimate of 14.00 and a low estimate of 9.00. The median estimate represents a +88.32% increase from the last price of 5.31.
The current consensus among 4 polled investment analysts is to Buy stock in Progenics Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.